Calyx and Qynapse Ink Partnership Deal Over Neuroimaging Analysis Tools

UK-based Calyx has teamed up with the French neuroimaging company Qynapse, gaining access to its QyScore and QPredict artificial intelligence-based image analysis tools.

QyScore, which analyzes magnetic resonance images of the brain to identify biomarkers that can help physicians make clinical care decisions, could “revolutionize the treatment of central nervous system disease,” the companies said.

The QPredict AI software, which predicts clinical disease progression based on a patient’s MRI and clinical data, has the potential to improve targeted patient selection in clinical trials, they said.

The partners aim to offer the image analysis tools to developers of treatments for Multiple Sclerosis, Parkinson’s, Alzheimer’s, and Huntington’s disease, as well as other neurodegenerative disorders.

The financial terms of the deal were not disclosed.